Is Avai Bio, Inc. (AVAI) a Buy, Sell, or Hold?
OTC : AVAI
Avai Bio, Inc.
$0.12 USD
-$0.01 (-4.0%)
- Volume
- 18.77K
- Average Volume
- 129.04K
- Market Capitalization
- $16.59M
- P/E Ratio
- -9.52
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.80
- Year Low
- $0.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.03
Company Overview
OTC
Chris Winter
Software - Application
Technology
AVAI
1
US
USD
Liquidity Metrics
-0.64
0.03
0.03
0.01
0.00
Sales & Valuation
-$
0.00
-5.95
-16.43
-0.01
Profitability
-$0.0127
-$1.75M
0.00%
0.00%
70.67%
-305.49%
P/E Metrics
-9.52
0.15
0.15
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-27.18
1/9
-$3.3M
$572.7K
$3.39M
-$1.55M
Key Metrics (TTM)
$18.36M
0.00
-12.07
0.03
70.67%
145.95%
-10.45%
-6.09%
-22302 days
Company Executives
| Name | Title |
|---|---|
| Vitalis Racius | CFO, Principal Financial & Accounting Officer, Treasurer and Director |
| Natalija Tunevic | Secretary & Director |
| Ivan Lunegov | President & Director |
| Chris Winter | Chief Executive Officer |
Poll Results
No votes yet today — be the first to share your view!
About Avai Bio, Inc. (OTC:AVAI) Stock
Avai Bio, Inc. operates as a holding company primarily focused on creating websites and mobile applications that offer users personalized and convenient experiences. Its business activities include providing IT consulting services and making artificial intelligence accessible to the general public. The company was established on November 6, 2017, and its main office is situated in Las Vegas, Nevada. ...
2026-07-22 07:30:00
KELOWNA, BC / ACCESS Newswire / July 22, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU) ("Avant" or the "Company"), is pleased to announce the successful completion of a comprehensive facility-wide lighting retrofit at the Company's largest cultivation facility, The Flowr Group Okanagan Inc. ("Flowr"), located in Kelowna, B.C. The project replaced traditional high-pressure sodium (HPS) fixtures with energy-efficient LED lighting across 100% of flower rooms, supported by funding from a Government of British Columbia energy efficiency incentive program.
2026-07-21 08:00:00
LAS VEGAS, July 21, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that, together with its joint venture partner Austrianova, it has successfully concluded negotiations and reached agreement on the terms of a collaboration with a premier, internationally acclaimed, partner to provide insulin-producing cells for Insulinova's groundbreaking diabetes therapy. Insulinova is a joint venture (JV) between Avaí and Austrianova, established in late 2025 to develop a revolutionary cell-based therapy for diabetes.
Avant Brands Reports Q2 2026 Results Highlighted by 34% Growth in Recreational Revenue
2026-07-15 08:30:00
KELOWNA, BC / ACCESS Newswire / July 15, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products, today released its financial results for the second quarter ended May 31, 2026 ("Q2 2026"). With an expanding global footprint, Avant has established itself as a leading Canadian producer of ultra-premium cannabis, delivering brands at a commercial volume that continues to be outpaced by market demand.
2026-05-20 08:45:00
LAS VEGAS, May 20, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a Master Cell Bank (MCB) of genetically modified cells that overexpress the α-Klotho protein. Now, the MCB will undergo comprehensive testing to confirm the absence of pathogenic viruses, as well as standard assays to verify the MCB is free from adventitious agents such as bacteria, mycoplasma, fungi, and yeast to meet regulatory expectations, including those set by the FDA.
Frequently Asked Questions
-
What is the current Avai Bio, Inc. (AVAI) stock price?
-
Avai Bio, Inc.(OTC:AVAI) stock price is $0.12 in the last trading session. During the trading session, AVAI stock reached the peak price of $0.8 while $0.11 was the lowest point it dropped to. The percentage change in AVAI stock occurred in the recent session was --4.0% while the dollar amount for the price change in AVAI stock was -$0.01.
-
AVAI's industry and sector of operation?
-
The OTC listed AVAI is part of Software - Application industry that operates in the broader Technology sector.
-
Who are the executives of AVAI?
-
Vitalis Racius | CFO, Principal Financial & Accounting Officer, Treasurer and Director
Natalija Tunevic | Secretary & Director
Ivan Lunegov | President & Director
Chris Winter | Chief Executive Officer
| -
How many employees does AVAI have?
-
Number of AVAI employees currently stands at 1. AVAI operates from 5348 Vegas Drive, Las Vegas, NV 89108, US.
-
Link for AVAI official website?
-
Official Website of AVAI is: https://avaibio.com
-
How do I contact AVAI?
-
AVAI could be contacted at phone #866 533 0065 and can also be accessed through its website. AVAI operates from 5348 Vegas Drive, Las Vegas, NV 89108, US.
-
How many shares of AVAI are traded daily?
-
The average number of AVAI shares traded daily for last 3 months was 129.04K.
-
What is the market cap of AVAI currently?
-
The market value of AVAI currently stands at $16.59M with its latest stock price at $0.12